153 related articles for article (PubMed ID: 33123753)
1. Reduction of derived neutrophil-to-lymphocyte ratio after four weeks predicts the outcome of patients receiving second-line chemotherapy for metastatic colorectal cancer.
Colloca GA; Venturino A; Guarneri D
Cancer Immunol Immunother; 2021 Apr; 70(4):1115-1125. PubMed ID: 33123753
[TBL] [Abstract][Full Text] [Related]
2. Neutrophil count and the inflammation-based glasgow prognostic score predict survival in patients with advanced gastric cancer receiving first-line chemotherapy.
Li QQ; Lu ZH; Yang L; Lu M; Zhang XT; Li J; Zhou J; Wang XC; Gong JF; Gao J; Li J; Li Y; Shen L
Asian Pac J Cancer Prev; 2014; 15(2):945-50. PubMed ID: 24568523
[TBL] [Abstract][Full Text] [Related]
3. Neutrophil-related Variables Have Different Prognostic Effect Based on Primary Tumor Location in Patients With Metastatic Colorectal Cancer Receiving Chemotherapy.
Colloca GA; Venturino A; Guarneri D
Clin Colorectal Cancer; 2019 Dec; 18(4):e343-e348. PubMed ID: 31351861
[TBL] [Abstract][Full Text] [Related]
4. Modern-day palliative chemotherapy for metastatic colorectal cancer: does colonic resection affect survival?
Lau JWL; Chang HSY; Lee KY; Gwee YX; Lee WQ; Chong CS
ANZ J Surg; 2018 Nov; 88(11):E772-E777. PubMed ID: 29938886
[TBL] [Abstract][Full Text] [Related]
5. Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy.
Shitara K; Yuki S; Yamazaki K; Naito Y; Fukushima H; Komatsu Y; Yasui H; Takano T; Muro K
J Cancer Res Clin Oncol; 2013 Apr; 139(4):595-603. PubMed ID: 23250506
[TBL] [Abstract][Full Text] [Related]
6. Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer.
Machida N; Yoshino T; Boku N; Hironaka S; Onozawa Y; Fukutomi A; Yamazaki K; Yasui H; Taku K; Asaka M
Jpn J Clin Oncol; 2008 Oct; 38(10):689-94. PubMed ID: 18845522
[TBL] [Abstract][Full Text] [Related]
7. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials.
van Soest RJ; Templeton AJ; Vera-Badillo FE; Mercier F; Sonpavde G; Amir E; Tombal B; Rosenthal M; Eisenberger MA; Tannock IF; de Wit R
Ann Oncol; 2015 Apr; 26(4):743-749. PubMed ID: 25515657
[TBL] [Abstract][Full Text] [Related]
8. Immune-related Genes to Dominate Neutrophil-lymphocyte Ratio (NLR) Associated With Survival of Cetuximab Treatment in Metastatic Colorectal Cancer.
Sunakawa Y; Yang D; Cao S; Zhang W; Moran M; Astrow SH; Hsiang J; Stephens C; Tsuji A; Takahashi T; Tanioka H; Negoro Y; Takagane A; Tani S; Yamaguchi T; Eto T; Fujii M; Ichikawa W; Lenz HJ
Clin Colorectal Cancer; 2018 Dec; 17(4):e741-e749. PubMed ID: 30219280
[TBL] [Abstract][Full Text] [Related]
9. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict chemotherapy outcomes and prognosis in patients with colorectal cancer and synchronous liver metastasis.
Wu Y; Li C; Zhao J; Yang L; Liu F; Zheng H; Wang Z; Xu Y
World J Surg Oncol; 2016 Nov; 14(1):289. PubMed ID: 27852294
[TBL] [Abstract][Full Text] [Related]
10. Derived neutrophil lymphocyte ratio is predictive of survival from intermittent therapy in advanced colorectal cancer: a post hoc analysis of the MRC COIN study.
Grenader T; Nash S; Adams R; Kaplan R; Fisher D; Maughan T; Bridgewater J
Br J Cancer; 2016 Mar; 114(6):612-5. PubMed ID: 26889974
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of monthly chemotherapy for patients with unresectable metastatic colorectal cancer.
Tomoda M; Kawahara H; Watanabe K; Enomoto H; Akiba T; Yanaga K
Anticancer Res; 2014 Jan; 34(1):191-4. PubMed ID: 24403461
[TBL] [Abstract][Full Text] [Related]
12. Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study.
Wood G; Grenader T; Nash S; Adams R; Kaplan R; Fisher D; Maughan T; Bridgewater J
Anticancer Drugs; 2017 Jun; 28(5):546-550. PubMed ID: 28252533
[TBL] [Abstract][Full Text] [Related]
13. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer.
Chua W; Charles KA; Baracos VE; Clarke SJ
Br J Cancer; 2011 Apr; 104(8):1288-95. PubMed ID: 21448173
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab in combination with chemotherapy in the first-line treatment of metastatic colorectal carcinoma.
Usakova V; Sevcikova K; Usak J; Bartosova Z; Mikulova M; Spanik S
Neoplasma; 2013; 60(1):83-91. PubMed ID: 23067221
[TBL] [Abstract][Full Text] [Related]
15. Neutrophil-lymphocyte ratio is a simple and novel biomarker for prediction of survival after radioembolization for metastatic colorectal cancer.
Tohme S; Sukato D; Chalhoub D; McDonald KA; Zajko A; Amesur N; Orons P; Marsh JW; Geller DA; Tsung A
Ann Surg Oncol; 2015 May; 22(5):1701-7. PubMed ID: 25190128
[TBL] [Abstract][Full Text] [Related]
16. Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy.
Giampieri R; Maccaroni E; Mandolesi A; Del Prete M; Andrikou K; Faloppi L; Bittoni A; Bianconi M; Scarpelli M; Bracci R; Scartozzi M; Cascinu S
Gastric Cancer; 2017 Jan; 20(1):156-163. PubMed ID: 26796888
[TBL] [Abstract][Full Text] [Related]
17. Practical use of capecitabine plus oxaliplatin (CAPEOX) with bevacizumab for patients with metastatic colorectal cancer that cannot expect conversion therapy.
Yokomizo H; Yoshimatsu K; Otani T; Osawa G; Nakayama M; Matsumoto A; Yano Y; Okayama S; Naritaka Y
Hepatogastroenterology; 2013; 60(128):1911-5. PubMed ID: 24719926
[TBL] [Abstract][Full Text] [Related]
18. Pre-treatment inflammatory indexes as predictors of survival and cetuximab efficacy in metastatic colorectal cancer patients with wild-type RAS.
Yang J; Guo X; Wang M; Ma X; Ye X; Lin P
Sci Rep; 2017 Dec; 7(1):17166. PubMed ID: 29215037
[TBL] [Abstract][Full Text] [Related]
19. Magnetic resonance imaging as an early indicator of clinical outcome in patients with metastatic colorectal carcinoma treated with cetuximab or panitumumab.
Ricotta R; Vanzulli A; Moroni M; Colnago B; Oriani M; Nichelatti M; Sarnataro C; Venturini F; Di Bella S; Maiolani M; Giganti MO; Sartore-Bianchi A; Siena S
Clin Colorectal Cancer; 2013 Mar; 12(1):45-53. PubMed ID: 23041354
[TBL] [Abstract][Full Text] [Related]
20. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
Huemer F; Thaler J; Piringer G; Hackl H; Pleyer L; Hufnagl C; Weiss L; Greil R
BMC Cancer; 2018 Jan; 18(1):11. PubMed ID: 29298682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
